An observational study in Acute Promyelocytic Leukemia, sponsored by Groupe Francophone des Myelodysplasies. Completed at 27 sites in France. Open to participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Groupe Francophone des Myelodysplasies · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.
134 studies on the registry are indexed under Leukemia, Promyelocytic, Acute; 16 are open to participants now.
This study's enrollment of 400 is above the median of 117 across 17 observational studies indexed under Leukemia, Promyelocytic, Acute.
Browse Leukemia, Promyelocytic, Acute studies →Groupe Francophone des Myelodysplasies is the lead sponsor of 44 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
French patients with newly-diagnosed de novo or therapy-related non-high-risk APL (White Blood Count \< 10000/μl) aged ≤ 70 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
according to usual practice center
according to usual practice center
Event-free survival
events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the consolidation courses; relapse; death including early death
Time frame: From date of induction until the date of first documented event, assessed up to 60 months
Rate of hematological complete remission
from date of inclusion until end of induction therapy
Time frame: up to 30 days
Rate of overall survival
Overall survival defined as the time from inclusion until death or end of follow-up
Time frame: at 5 years
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2015, a primary completion of Jul 2026 and a completion of Jul 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Promyelocytic, Acute →
Groupe Francophone des Myelodysplasies